Genzyme Asks For Campath Label Expansion To First-Line Lymphocytic Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Data supporting the B-cell lymphocytic leukemia sBLA also completes Campath’s 2001 Phase IV obligation.
You may also be interested in...
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme Plans Campath MS Launch In 2009
Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.